VLT-201
Phase 2Moderate-to-severe ulcerative colitis
A gut-restricted modulator of pathogenic Th17 signalling, designed to reduce mucosal inflammation with limited systemic exposure.
Clinical-stage biopharmaceutical company
Translating immune science into medicines that endure
We design targeted therapeutics for autoimmune and inflammatory disease, guided by human biology and validated by rigorous translational research.
4
Programs in clinical development
12
Years of translational research
3
Global research collaborations
A focused pipeline, built on validated targets
Every Veltara program begins with a human genetic or clinical signal, and advances only when the translational evidence holds.
VLT-118
Phase 1Systemic lupus erythematosus
A first-in-class antibody targeting an interferon-driven B cell axis identified in patient tissue profiling.
VLT-340
Phase 1Idiopathic pulmonary fibrosis
A selective fibroblast activation inhibitor intended to slow progressive lung remodelling.
VLT-405
PreclinicalCutaneous lupus erythematosus
A locally applied candidate under IND-enabling study for chronic cutaneous disease.
The Veltara platform
Our discovery engine pairs deep immunophenotyping of patient tissue with computational target selection, so we pursue mechanisms that matter in people rather than models alone.
Explore the platformLatest news
Press release
Veltara doses first patient in Phase 2 study of VLT-201 in ulcerative colitis
The randomised, double-blind study will evaluate mucosal healing at week 12 across approximately 180 patients.
18 June 2026
Publication
Veltara scientists publish single-cell atlas of inflamed intestinal tissue
The dataset describes immune cell states across 214 patient biopsies and is available to the research community.
2 April 2026
Press release
Veltara completes $145 million Series C financing
Proceeds will fund the Phase 2 program for VLT-201 and advance two discovery candidates toward IND.
21 January 2026
Partner with us
We collaborate with academic groups, patient organisations and biopharma partners who share our commitment to disciplined science.
Get in touch